ACST.V - Acasti Pharma Inc.

TSXV - TSXV Delayed Price. Currency in CAD
1.0100
-0.0300 (-2.88%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close1.0400
Open1.0600
Bid1.0100 x 0
Ask1.0200 x 0
Day's Range1.0000 - 1.0600
52 Week Range0.6700 - 4.0500
Volume241,818
Avg. Volume267,441
Market Cap88.834M
Beta (5Y Monthly)0.41
PE Ratio (TTM)N/A
EPS (TTM)-0.7930
Earnings DateFeb 11, 2020 - Feb 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.79
  • This Biotech Stock Is Flying High After Rival Heart Drugs Stumbled
    Investor's Business Daily

    This Biotech Stock Is Flying High After Rival Heart Drugs Stumbled

    Amarin stock popped Monday after rivals AstraZeneca and Acasti Pharma reported disappointing outcomes for their Vascepa-rivaling high triglycerides treatments.

  • GlobeNewswire

    Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre

    Reports 30.5% and 36.7% reduction in triglyceride levels, compared with baseline, among patients receiving CaPre at 12 and 26 weeks respectively, as well as 42.2% reduction in.

  • 3 Healthcare Stocks With Big Catalysts in January
    TipRanks

    3 Healthcare Stocks With Big Catalysts in January

    When searching for the stocks that can see explosive growth overnight, look no further than the healthcare industry. Unlike other names, healthcare companies often rely on only a few key milestones like data readouts or FDA approvals. So, when a particular result goes a company’s way, the news can act as a catalyst that sends shares soaring. However, investors looking to gain exposure to this space should know that this also makes these stocks riskier as unfavorable outcomes can have the opposite effect.As a result, the strength of investment opportunities in this sector can be harder to determine. So what’s the best way to gauge healthcare stocks ahead of big catalysts? We suggest turning to Wall Street analysts for guidance.Using TipRanks, an investing platform that measures and tracks the performance of analysts, we were able to access market data on 3 stocks as they approach significant catalysts this month, including what the analysts have to say about each. The platform also revealed that all of these Strong Buy tickers boast impressive upside potential from current levels. Here’s the diagnosis.Acasti Pharma (ACST)Like headline-making biotech Amarin, Acasti Pharma focuses on the development and commercialization of prescription drugs using omega-3 fatty acids. The company’s lead candidate, CaPre, is currently progressing through a Phase 3 program for severe hypertriglyceridemia, a condition that leads to abnormally high levels of triglycerides in the bloodstream. With new CaPre TRILOGY 1 and 2 trial data expected this month, all eyes are on ACST.While top-line data from the TRILOGY 1 trial was originally slated for December, the company had to delay the readout as a result of a delay in data processing and transfer from the central testing laboratory to the statistical consultants for independent and external validation. Even though the delay was technical in nature, some investors were not impressed.That being said, Oppenheimer analyst Leland Gershell remains unphased. “With the complex logistics and enormity of work required of several people to process Phase 3 trial results bumping up against the holidays and their attendant slowdown, we are not surprised to learn that the report of top-line data from CaPre's TRILOGY 1 will slip past December… Our expectation for a positive trial outcome is unchanged, and we recommend investors take advantage of the current weakness,” he explained. Bearing this in mind, the five-star analyst maintained an Outperform rating and $7 price target, implying a potential twelve-month gain of 220%. (To watch Gershell’s track record, click here)Like Gershell, Aegis Capital’s Nathan Weinstein sides with the bulls. After an FDA AdCom voted unanimously to expand Amarin’s Vascepa label to include cardiovascular risk, the analyst believes that ACST stands to benefit. “In many ways we think it’s still early days in this brave new iteration of the prescription omega-3 category, where enhanced attention is being paid to composition, potential cardiovascular risk reduction benefits, and potentially other patient benefits…To the extent there end up being multiple positive outcomes trials in the space across both EPA only and mixed EPA/DHA compositions, we think that could lend credence to the view that cardiovascular risk reduction is a an effect of omega-3 medications not limited to a pure EPA composition,” he commented. To this end, Weinstein left his Buy rating and $3 price target as is.Looking at the consensus breakdown, 100% of the analysts covering ACST see it as a Buy, making the consensus rating a unanimous Strong Buy. Additionally, the $6.02 average price target puts the upside potential at 175%. (See Acasti stock analysis on TipRanks)VBI Vaccines Inc. (VBIV) VBI Vaccines is best known for developing vaccines for immuno-oncology and infectious diseases. Its hepatitis B vaccine, Sci-B-Vac, has already been approved in Israel and ten other countries, with it currently in a Phase 3 program in the U.S., Canada and Europe. Ahead of the data readout for Sci-B-Vac in the next few weeks, Canaccord's John Newman likes what he’s seeing.The analyst tells clients that he expects the top-line Phase 3 CONSTANT trial data to demonstrate the efficacy of the vaccine, and should include immune repression measures such as geometric mean concentration (GMC) of antibodies across the three independent manufactured groups of Sci-B-Vac. “We continue to believe Sci-B-Vac will be viewed positively by regulators and achieve approval in the US and EU after positive readout in CONSTANT in January 2020. We look forward to an update of two-dose noninferiority data with inclusion of patients from the CONSTANT dataset,” he wrote in a note to clients.On top of this, Newman cites its VBI-1901 candidate for glioblastoma multiforme (GBM) and VBI-1501A for cytomegalovirus (CMV) infection as key points of strength for the company, expecting continued positive data from each.He further added, “Brii Bio and VBI plan to initiate enrollment of a phase 1b/2a proof-of-concept study in subjects with chronic HBV infection in 4Q19E which could allow for initial first-inhuman proof of concept data readout in 2H20E.”Based on all the above factors, the five-star analyst reiterated his bullish call. While Newman did reduce the price target from $5 to $4, this still conveys his confidence in VBIV’s ability to climb 270% higher in the next twelve months. (To watch Newman’s track record, click here)What does the rest of the Street think? Given that 3 Buys and no Holds or Sells have been assigned in the last three months, the stock earns a Strong Buy consensus rating. Not to mention the $3.67 average price target brings the upside potential to 170%. (See VBI Vaccines stock analysis on TipRanks)Veru Inc. (VERU) Veru uses a novel approach to develop and commercialize medicines for prostate cancer. According to one analyst, 2020 could be a big year for Veru, starting with the announcement of new top-line Phase 2 data for Zuclomiphene citrate for hot flashes caused by prostate cancer hormone therapy.The readout, which is scheduled for this month, is an interim topline look at the frequency of hot flashes as well as the safety of the 10mg and 50mg doses. Brandon Folkes of Cantor Fitzgerald notes that a clinically meaningful reduction in hot flashes for Zuclomiphene Citrate is between 11% and 26%, which is how he thinks the treatment will be evaluated by the FDA. In addition, the company's recent FY4Q19 earnings release indicates that there haven’t been cases of side effects like gynecomastia, breast pain or venothromboembolic events (blood clots in legs or lungs, or stroke) that are typically associated with off label use of steroidal estrogens and progestins for hot flashes.“Thus given the lack of these common side effects being seen in the Phase 2 trial, we expect VERU to move forward to test the 100mg dose, which will require 30 patients. We believe that decision should be viewed as a positive. Given that zuclomiphene is an estrogen, we would expect to see dose dependent efficacy in Zuclomiphene citrate, and the lack of safety concerns which enable VERU to move to test the higher 100mg dose is likely to result in a more compelling product offering, should the product come to market,” Folkes stated.To top it off, Phase 1b data from VERU-111 for castration resistant metastatic prostate cancer is expected in early 2020, with Veru already indicating that there’s evidence of substantial antitumor activity.All of this prompted Folkes to maintain a Buy rating along with a $6 price target. At this target, a 67% twelve-month rise could be in the cards. (To watch Folkes’ track record, click here)Turning now to other analysts, they appear to be on the same page. With 3 Buys compared to no Holds or Sells, the message is clear: Veru is a Strong Buy. The average price target of $5.83 suggests 62% upside potential, just below Folkes’ forecast. (See Veru stock analysis on TipRanks)

  • Benzinga

    Acasti Delays Data Readout For Drug To Treat Elevated Triglycerides

    Micro-cap biopharma Acasti Pharma Inc (NASDAQ: ACST) issued an update regarding a delay in a clinical readout. Acasti said late Monday it's postponing the release of top-line results for the TRILOGY 1 pivotal Phase 3 study of CaPre to January, citing an unexpected delay in data processing and transfer from the central testing laboratory to the statistical consultants for independent and external validation. CaPre, a highly purified omega-3 phospholipid concentrate derived from krill oil, is being developed to treat severe hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreatitis.

  • Benzinga

    Benzinga Pro's Top 5 Stocks To Watch For Tues., Dec. 24, 2019: TSLA, WCC, ACST, YMAB, ITCI

    Benzinga Pro's Stocks To Watch For Tuesday Tesla (TSLA) - Shares moved over the controversial "funding secured" $420 level which Elon Musk famously tweeted about in the summer of 2018. The intraday ...

  • GlobeNewswire

    Acasti Pharma Provides Update on Timing of Topline Results for TRILOGY 1 Phase 3 Trial of CaPre

    Acasti regrets the delay due to factors outside its control, and now anticipates to report topline results in January 2020. As requested by the Investment Industry Regulatory Organization of Canada (IIROC), due to market volatility, the Company indicates that it has no material update to provide at this time beyond the above timing update and independent and external validation exercise that is underway.

  • CNW Group

    IIROC Trading Halt - ACST

    IIROC Trading Halt - ACST

  • Hedge Funds Have Never Been This Bullish On Acasti Pharma Inc. (ACST)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Acasti Pharma Inc. (ACST)

    The market has been volatile in the last few months as the Federal Reserve finalized its rate cuts and uncertainty looms over trade negotiations with China. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by more than 10 percentage […]

  • GlobeNewswire

    Acasti Pharma Reports Last Patient Visit in TRILOGY 1 Phase 3 Trial of CaPre for the Treatment of Severe Hypertriglyceridemia

    LAVAL, Québec, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (triglyceride blood levels from 500 mg/dL to 1500 mg/dL), announced that the last patient completed their final visit in the Company's TRILOGY 1 pivotal Phase 3 trial of CaPre last week. Topline results for TRILOGY 1 are expected to be reported as planned in December 2019.

  • Encode Ideas, L.P. Announces the Initiation of Research Coverage on Acasti Pharma, Inc.
    Newsfile

    Encode Ideas, L.P. Announces the Initiation of Research Coverage on Acasti Pharma, Inc.

    Dover, Delaware--(Newsfile Corp. - November 25, 2019) - Encode Ideas, L.P. Initiates Research on Acasti Pharma, Inc. (NASDAQ: ACST). The full research publication is available here and available on our website at www.encodelp.com. Encode Ideas is initiating coverage on Acasti Pharma, Inc. as a high-risk investment idea. Acasti is developing a krill-based omega-3 fatty acid product, CaPre, for the treatment of severe hypertriglyceridemia. Acasti is currently conducting two virtually identical Ph3 studies - ...

  • GlobeNewswire

    Acasti Pharma Releases Preliminary New Animal Data, and Gains Insights Into CaPre’s Novel Mechanism of Action in Diabetes

    Despite the lower concentration of EPA in CaPre’s composition, the actual levels of 18RS-HEPE (a metabolite of EPA) reached in the blood were higher for CaPre than levels produced by icosapent ethyl. 18RS-HEPE and Resolvin E1 are both involved in the resolution of inflammation that is triggered in many chronic diseases including obesity and diabetes.

  • GlobeNewswire

    Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2020

    LAVAL, Québec, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (triglyceride blood levels from 500 mg/dL to 1500 mg/dL), today provided a business update and announced its operating and financial results for the second quarter of fiscal 2020 ended September 30, 2019. “Assuming our TRILOGY trials replicate our Phase 2 data, we believe CaPre has the potential to become a best-in-class omega-3, due to both the Trifecta Effect and greater bioavailability, especially in patients that follow the standard physician-recommended, restricted low-fat diet.

  • GlobeNewswire

    Acasti Pharma Announces Publication of CaPre Pharmacokinetics Study in a Leading Peer-Reviewed Journal

    LAVAL, Québec, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today announced the publication as Articles in Press of a CaPre pharmacokinetics study, entitled, “Evaluation of OM3-PL/FFA Pharmacokinetics After Single and Multiple Oral Doses in Healthy Volunteers” in a leading peer-reviewed journal, Clinical Therapeutics. The study publication is available online and can be accessed at: https://www.clinicaltherapeutics.com/article/S0149-2918(19)30499-0/fulltext .

  • GlobeNewswire

    Acasti Pharma Schedules Second Quarter Fiscal 2020 Conference Call

    Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today announced that it will host a conference call at 1:00 PM Eastern Time on Wednesday, November 13, 2019 to discuss the Company’s financial results for the second quarter ended September 30, 2019, as well as the Company’s corporate progress and other developments. The conference call will be available via telephone by dialing toll free 844-369-8770 for U.S. callers or +1 862-298-0840 for international callers, or on the Company’s News and Investors section of the website: https://www.acastipharma.com/investors/.

  • GlobeNewswire

    Acasti Pharma Partners with Aker BioMarine to Supply Krill Oil for CaPre®

    LAVAL, Québec, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it has partnered with Aker BioMarine to deliver krill oil to Acasti, under a two-year, fixed price supply agreement. Raw Krill Oil (RKO) is the starting material used by Acasti to make CaPre, which is then further processed via a series of complex and proprietary extraction and purification manufacturing steps to produce the drug substance for CaPre.

  • GlobeNewswire

    Acasti Pharma to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    LAVAL, Québec, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it will be presenting at the 2019 Cantor Fitzgerald Global Healthcare Conference being held on October 2-4, 2019 at the InterContinental New York Barclay Hotel in New York City. Jan D’Alvise, Chief Executive Officer, is scheduled to present on Wednesday, October 2, 2019 at 7:45 a.m. Eastern Time with one-on-one meetings being held throughout the day.

  • GlobeNewswire

    Acasti Pharma Announces Additional Phase 3 Milestones Reached, and Remains on Track to Report Topline Results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020

    Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today reported additional milestones reached and provided a business update on its clinical trials. Pierre Lemieux, Ph.D., COO and CSO of Acasti, commented, “Our TRILOGY Phase 3 trials in patients with severe hypertriglyceridemia (triglyceride blood levels from 500 mg/dL to 1500 mg/dL) continue to progress, and we remain on track to report topline TRILOGY 1 results in December 2019, and topline TRILOGY 2 results in January 2020. Jan D’Alvise, president and CEO of Acasti, further noted, “Given the positive results we saw from our Phase 2 trials in a total of 675 patients, we eagerly await the completion of the results from our two TRILOGY clinical studies.

  • Do Insiders Own Lots Of Shares In Acasti Pharma Inc. (CVE:ACST)?
    Simply Wall St.

    Do Insiders Own Lots Of Shares In Acasti Pharma Inc. (CVE:ACST)?

    Every investor in Acasti Pharma Inc. (CVE:ACST) should be aware of the most powerful shareholder groups. Insiders...

  • GlobeNewswire

    Acasti Pharma Receives Funding from the Government of Canada to Expand Production Capacity

    Acasti Pharma Inc. (“Acasti” or the “Company”)  (NASDAQ: ACST – TSX-V: ACST) a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today announced that the Company has been awarded up to $750,000 in non-dilutive and non-repayable funding, as well as technical and business advisory services, from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to apply towards research and development of the Company’s unique commercial production platform for CaPre. With NRC IRAP support, Acasti aims to expand and enhance its production capabilities for CaPre.

  • GlobeNewswire

    Acasti Pharma to Present at the 21st Annual Rodman & Renshaw Global Investment Conference in New York City on September 9th

    LAVAL, Québec, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it will be presenting at the 21st Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, being held on September 8-10, 2019 at the Lotte New York Palace Hotel in New York City. Jan D’Alvise, Chief Executive Officer, is scheduled to present on Monday, September 9, 2019 at 9:35 a.m. Eastern Time. If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.rodmanevents.com) to register for the conference.

  • GlobeNewswire

    Acasti Pharma Announces the Election of Its Directors, Amendments to Its Stock Option and Equity Incentive Plans and Other Related Matters Approved at Its AGM

    LAVAL, Quebec, Aug. 28, 2019 -- Acasti Pharma Inc. (“Acasti” or the “Corporation”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research,.

  • GlobeNewswire

    Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2020

    LAVAL, Québec, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today provided a business update and announced its operating and financial results for the first quarter of fiscal 2020 ended June 30, 2019. Jan D’Alvise, president and CEO of Acasti Pharma, commented, “Our TRILOGY Phase 3 trials in patients with severe hypertriglyceridemia (triglyceride blood levels from 500 mg/dL to 1500 mg/dL) continue to progress, and we remain on track to report topline TRILOGY 1 results in December 2019, and topline TRILOGY 2 results in January 2020.

  • GlobeNewswire

    Acasti Pharma Co-Founder, Chief Operating and Scientific Officer to Participate on Lipid Panel at the 2019 BTIG Biotechnology Conference

    LAVAL, Québec, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today announced that the Company will be participating on a panel during the 2019 BTIG Biotechnology Conference being held on Monday, August 12th, at the St. Regis in New York City. Its omega-3s, principally EPA and DHA, are either “free” or bound to phospholipids, which allows for better absorption into the body.

  • GlobeNewswire

    Acasti Pharma Schedules First Quarter Fiscal 2020 Conference Call

    LAVAL, Québec, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today announced that it will host a conference call at 1:00 PM Eastern Time on Wednesday, August 14, 2019 to discuss the Company’s financial results for the first quarter ended June 30, 2019, as well as the Company’s corporate progress and other developments. The conference call will be available via telephone by dialing toll free 844-369-8770 for U.S. callers or +1 862-298-0840 for international callers, or on the Company’s News and Investors section of the website: https://www.acastipharma.com/investors/.

  • GlobeNewswire

    Acasti Pharma Comments on Trading Activity and Reaffirms No Plans to Raise Capital

    The Company also noted several recently issued independent analyst reports issued by third-party investment banks, which highlighted the current Phase 3 TRILOGY clinical studies for CaPre® and anticipated topline results for the primary endpoint of lowering triglycerides for TRILOGY 1 in December 2019, and for TRILOGY 2 in January 2020.  The Company does not endorse the content, recommendations or price targets of any third-party reports. The Company also reaffirmed it has no current plans to raise capital and management believes Acasti is sufficiently capitalized beyond completion of the Phase 3 trials.